Recombinant protein · Agonist of follicle-stimulating hormone receptor (FSHR) · developed by Organon Usa
Follitropin beta is a recombinant follicle-stimulating hormone given by subcutaneous injection in fixed daily doses during ovarian stimulation. It acts on the follicle-stimulating hormone receptor to stimulate follicle development. It is studied in female infertility and ovarian function insufficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05330130 | Phase 1 | Ovarian Function Insufficiency | Completed | OGN |
| NCT00703014 | N/A | Pregnancy | Completed | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fertility IssuesInfertilityInfertility,FemaleNeonatesOvarian Function InsufficiencyPregnancy
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →